GALAPAGOS REPORTS PRIMARY ENDPOINT FOR THE ONGOING FILGOTINIB MANTA AND MANTA-RAy SAFETY STUDIES
Galapagos NV - American Depositary Shares (GLPG)
Last galapagos nv - american depositary shares earnings: 10/24 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
glpg.com/company-overview
Company Research
Source: GlobeNewswire
8.3% patients on placebo and 6.7% patients on filgotinib had a 50% or more decline in sperm concentration at week 13No new safety findings were identifiedData will be submitted to the relevant regulatory authorities Mechelen, Belgium, 4 March 2021, 07.40 CET, regulated information –Galapagos NV (Euronext & Nasdaq: GLPG) today announced interim results from MANTA and MANTA-RAy, two ongoing safety studies investigating the effect of Jyseleca® (filgotinib) on sperm parameters in males with inflammatory bowel disease (MANTA) or rheumatic conditions (MANTA-RAy). In total, 248 patients were randomized 1:1 to receive filgotinib 200 mg once daily or placebo for an initial 13-week, double-blind treatment period. The primary endpoint in both trials was the proportion of patients who had a reduction of 50% or more in sperm concentration at Week 13. Patients who met this endpoint discontinued study treatment at Week 13, were switched to standard of care treatment and were monitored f
Show less
Read more
Impact Snapshot
Event Time:
GLPG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLPG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLPG alerts
High impacting Galapagos NV - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GLPG
News
- Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024 [Yahoo! Finance]Yahoo! Finance
- Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024GlobeNewswire
- Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders' Meetings [Yahoo! Finance]Yahoo! Finance
- Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ MeetingsGlobeNewswire
- Galapagos NV (NASDAQ: GLPG) had its "underperform" rating re-affirmed by analysts at Bank of America Co.. They now have a $31.00 price target on the stock, down previously from $41.00.MarketBeat
GLPG
Earnings
- 5/4/23 - Beat
GLPG
Sec Filings
- 4/8/24 - Form 6-K
- 3/29/24 - Form 6-K
- 3/29/24 - Form 6-K
- GLPG's page on the SEC website